Cargando…

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies

The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use for the treatment of numerous cancers. However, approximately only a third of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez, Carlos, Arasanz, Hugo, Chocarro, Luisa, Bocanegra, Ana, Zuazo, Miren, Fernandez-Hinojal, Gonzalo, Blanco, Ester, Vera, Ruth, Escors, David, Kochan, Grazyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177687/
https://www.ncbi.nlm.nih.gov/pubmed/32244396
http://dx.doi.org/10.3390/ijms21072411
_version_ 1783525274163347456
author Hernandez, Carlos
Arasanz, Hugo
Chocarro, Luisa
Bocanegra, Ana
Zuazo, Miren
Fernandez-Hinojal, Gonzalo
Blanco, Ester
Vera, Ruth
Escors, David
Kochan, Grazyna
author_facet Hernandez, Carlos
Arasanz, Hugo
Chocarro, Luisa
Bocanegra, Ana
Zuazo, Miren
Fernandez-Hinojal, Gonzalo
Blanco, Ester
Vera, Ruth
Escors, David
Kochan, Grazyna
author_sort Hernandez, Carlos
collection PubMed
description The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use for the treatment of numerous cancers. However, approximately only a third of the patients benefit from ICI therapies. Many efforts have been made for the identification of biomarkers allowing patient stratification into potential responders and progressors before the start of ICI therapies or for monitoring responses during treatment. While much attention is centered on biomarkers from the tumor microenvironment, in many cases biopsies are not available. The identification of systemic immune cell subsets that correlate with responses could provide promising biomarkers. Some of them have been reported to influence the response to ICI therapies, such as proliferation and activation status of CD8 and CD4 T cells, the expression of immune checkpoints in peripheral blood cells and the relative numbers of immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells. In addition, the profile of soluble factors in plasma samples could be associated to response or tumor progression. Here we will review the cellular subsets associated to response or progression in different studies and discuss their accuracy in diagnosis.
format Online
Article
Text
id pubmed-7177687
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71776872020-04-28 Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies Hernandez, Carlos Arasanz, Hugo Chocarro, Luisa Bocanegra, Ana Zuazo, Miren Fernandez-Hinojal, Gonzalo Blanco, Ester Vera, Ruth Escors, David Kochan, Grazyna Int J Mol Sci Review The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use for the treatment of numerous cancers. However, approximately only a third of the patients benefit from ICI therapies. Many efforts have been made for the identification of biomarkers allowing patient stratification into potential responders and progressors before the start of ICI therapies or for monitoring responses during treatment. While much attention is centered on biomarkers from the tumor microenvironment, in many cases biopsies are not available. The identification of systemic immune cell subsets that correlate with responses could provide promising biomarkers. Some of them have been reported to influence the response to ICI therapies, such as proliferation and activation status of CD8 and CD4 T cells, the expression of immune checkpoints in peripheral blood cells and the relative numbers of immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells. In addition, the profile of soluble factors in plasma samples could be associated to response or tumor progression. Here we will review the cellular subsets associated to response or progression in different studies and discuss their accuracy in diagnosis. MDPI 2020-03-31 /pmc/articles/PMC7177687/ /pubmed/32244396 http://dx.doi.org/10.3390/ijms21072411 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hernandez, Carlos
Arasanz, Hugo
Chocarro, Luisa
Bocanegra, Ana
Zuazo, Miren
Fernandez-Hinojal, Gonzalo
Blanco, Ester
Vera, Ruth
Escors, David
Kochan, Grazyna
Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
title Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
title_full Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
title_fullStr Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
title_full_unstemmed Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
title_short Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
title_sort systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177687/
https://www.ncbi.nlm.nih.gov/pubmed/32244396
http://dx.doi.org/10.3390/ijms21072411
work_keys_str_mv AT hernandezcarlos systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies
AT arasanzhugo systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies
AT chocarroluisa systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies
AT bocanegraana systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies
AT zuazomiren systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies
AT fernandezhinojalgonzalo systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies
AT blancoester systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies
AT veraruth systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies
AT escorsdavid systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies
AT kochangrazyna systemicbloodimmunecellpopulationsasbiomarkersfortheoutcomeofimmunecheckpointinhibitortherapies